Huons Global said Monday that it has signed a 35 billion won ($31.4-million) deal with Health-MIUMIU, a Chinese dental company, for supplying local anesthesia lidocaine and epinephrine 1:100,000 injections.

Under the accord, the Korean company will likely generate sales for five years after it won a local license in the latter half of 2022.

Huons Global will be the first company to provide lidocaine with epinephrine injection to China. So far, only ampoules and vial formulation of lidocaine injections have been available for use in the Chinese dental local anesthetic market.

Huons Global's cartridge formulation can be directly connected to an injector, providing safe use by preventing bacterial infection, unlike the vials and ampoules distributed in China, the company said. It will expand marketing in China to secure more than 50 percent of the local anesthetics market containing epinephrine before the contract ends.

China's local anesthetic market containing epinephrine is estimated to be about 51 billion won.

Huons Global's local anesthetics have passed the Food and Drug Administration screening three times, entering the U.S. pharmaceutical market armed with its product’s excellent productivity, technology, and quality.

The company will supply lidocaine and epinephrine injections using its partner's distribution network, which has signed contracts with more than 60 percent of dental clinics across China and large supply centers in four major regions.

"Huons have been distributing local anesthetics to 20 countries, including the U.S., and our products were recognized for excellent quality and technology," said Yoon Sung-tae, vice chairman of Huons Global. "We will lead the Chinese anesthetic market with great quality, scarcity of cartridge formulations, and a strong network of Health-MIUMIU."